Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$7.63 USD
-0.09 (-1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $7.64 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.63 USD
-0.09 (-1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $7.64 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Zacks News
Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod
by Zacks Equity Research
Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.
Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod
by Zacks Equity Research
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response
by Zacks Equity Research
Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low
by Zacks Equity Research
Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast. Stock down in pre-market trading.
What's in the Cards for Eli Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.
Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo
by Zacks Equity Research
Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
by Zacks Equity Research
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.
CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.
Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More
by Zacks Equity Research
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.
Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint
by Zacks Equity Research
Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.
Kaleido (KLDO) Reports Positive Results from COVID-19 Study
by Zacks Equity Research
Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.
Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive data from a phase III study on its antibody cocktail for COVID-19.
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk
by Zacks Equity Research
Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.
Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Lilly (LLY) COVID-19 Antibody Combo Cuts Death/Hospitalization
by Zacks Equity Research
Lilly's (LLY) combination of its antibody drugs, bamlanivimab and etesevimab cuts death and hospitalizations, per new data from the BLAZE-1 phase III study.
Lilly (LLY) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.
Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod
by Zacks Equity Research
CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.